In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novacept: A Patient Device Exit Strategy Succeeds

Executive Summary

Using an aggressive clinical trials strategy to overcome early setbacks, Novacept is proof a small company can succeed in a big company market, and that a patient exit strategy can pay off for device companies--evidenced by Cytyc's $325 million cash acquisition of Novacept.
Advertisement

Related Content

Building Interventional Gynecology
Device Exits Can Rival Biotech, But Watch Out for the Risks
Conceptus' Re-Birth: Surviving in Women's Health
Conceptus' Re-Birth: Surviving in Women's Health
More from the Device Innovators' Workbench
More from the Device Innovators' Workbench
Impres Medical Inc.
Rodney Perkins: The Physician as Device Entrepreneur
Rodney Perkins: The Physician as Device Entrepreneur
Novacept

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel